BCM
HUMA icon

Bayesian Capital Management’s Humacyte HUMA Stock Holding History

Bayesian Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,641
Closed -$37K – 878
2023
Q3 		$37K Buy
12,641
+2,100
+20% +$6.95K ﹤0.01% 648
2023
Q2 		$30.1K Buy
+10,541
New +$38K ﹤0.01% 738

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Bayesian Capital Management's HUMA Position: Q4 2023 in Review

Bayesian Capital Management sold out of Humacyte (HUMA) in Q4 2023, closing a stake of 12,641 shares — an estimated $37K sold.

Bayesian Capital Management first reported a position in HUMA in Q2 2023 and held it in 2 quarters. The position peaked at $37K in Q3 2023. 88 funds tracked by Wall St. Rank hold HUMA as of Q4 2023.

  • Bayesian Capital Management reported no remaining Humacyte position as of Q4 2023 after selling out during the quarter.
  • Bayesian Capital Management sold 12,641 Humacyte shares in Q4 2023, an estimated $37K.
  • Bayesian Capital Management first reported a position in Humacyte in Q2 2023 and held it in 2 quarters.
  • Bayesian Capital Management's Humacyte position peaked at $37K in Q3 2023.
  • 88 funds tracked by Wall St. Rank held Humacyte as of Q4 2023.

Based on Bayesian Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.